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Introduction
Clearance mechanisms for rFVII (or the active enzyme
rFVIIa) and rFIX are influenced by post-translational
modifications, especially N-glycosylation. This should be
considered when choosing a recombinant expression
system in view of the varying ability of frequently used
cell lines to perform modifications similar to human
proteins.
Differences in the pharmacokinetic properties of
recombinant FVIIa versus plasma-derived (pd)FVII or
desialylated rFVIIa are known for human FVII(a). Asialo
rFVIIa clears quickest, whereas pdFVII, having a higher
degree of sialylation, is cleared to a lesser extent [1]. In
the case of FIX, the degrees of serine phosphorylation
and tyrosine sulfation in the activation peptide have
been postulated to influence pharmacokinetic behavior,
especially in vivo recovery [2].
We chose CHO, BHK and HEK293 cells for expres-
sion of rFVII to compare post-translational protein
modifications, and HEK293-derived cell lines to generate
highly phosphorylated and sulfated rFIX for in vivo stu-
dies. rFIX from the same clone and production run was
purified using two different down-stream processes: The
first to enrich high phosphorylated and sulfated protein,
the second to purify total rFIX at high yield. These
HEK293-derived rFIX isoforms were compared with
CHOrFIX and pdFIX in a pharmacokinetic study in FIX
knock-out mice.
Materials and methods
Proteins
pdFVII and pdFIX were from HTI, recombinant, CHO-
derived FIX was from Wyeth.
Cell culture
BHK (BHK-21; ATCC#CCL-10™) and HEK293 cells
(ATCC#1531) were from American Type Culture Col-
lection, CHO DXB11 from University of Columbia. All
were cultivated in DMEM/Ham’s F12 medium contain-
ing fetal bovine serum (FBS). BHK and HEK293 cell-
derived rFVII producer clones were selected by antibio-
tic resistance. CHO DXB11-derived producer clones
were generated by methotrexate gene co-amplification.
rFVII was produced in vitamin K-containing medium
without FBS.
HEK293 cells producing human FIX were selected by
antibiotic resistance. Clones were adapted to serum-free
suspension culture in Excell293 medium containing vita-
min K, and cultivated in repeated batch mode fermenta-
tion runs.
Purification
rFVII was purified using Q-Sepharose FF for capture,
and a tandem step containing a cellufine sulfate column
connected to Q-Sepharose FF.
HEK293-derived rFIX from the same clone from one
fermentation run was purified from culture supernatants
with two different purification schemas: for high yield,
rFIX was loaded in the presence of EDTA on Q-Sephar-
ose FF, the column was washed with EDTA at high salt
concentration, FIX was eluted at low salt CaCl2. For
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protein fraction, rFIX was loaded in the presence of
EDTA on fractogel TMAE, washed with EDTA at high
salt concentration, and eluted with a salt gradient in the
presence of CaCl2.
Analytics
Purified FVII forms were analyzed using reversed phase
HPLC, LC-MS for intact protein or peptide mapping
after trypsin digestion to confirm sequences and post-
translational modifications, and anion exchange HPLC
for monosaccharide composition, sialic acid quantifica-
tion, and comparison of N-glycans.
Degrees of FIX-phosphorylation/sulfation were moni-
tored by LC-MS. N-glycosylation was characterized by
oligosaccharide mapping (HPLC method).
In vivo pharmacokinetic study
FIX preparations were administered to FIX-knock-out
mice intravenpusly at a nominal dose of 75 U/kg.
Citrate plasmas were obtained by heart puncture. FIX
levels in plasmas were determined by antigen enzyme-
linked immunoassay and by activated partial thrombo-
plastine time (APTT) clotting assay.
Results and conclusions
Identical protein structures and minor differences in
post-translational modifications between rFVII from
BHK, CHO, HEK293 cells, and pdFVII were found,
except for N-glycosylation. Protein activities of rFVII
determined by antigen and activity assays were similar
for each cell type. Most N-glycans of pdFVII are bi- and
triantennary, non-fucosylated structures with almost
complete sialylation [3]. In contrast, all rFVII forms
were sialylated only in part. Approximately 50 % N-gly-
cans of BHKrFVII were composed of a core-fucosylated
biantennary complex-type with two terminal sialic acids.
Another 20 % contained terminal GalNAc, a sugar moi-
ety with a high affinity for the asialoglycoprotein recep-
tor involved in the in vivo clearance of glycoproteins
Figure1 Pharmacokinetic comparison of pdFIX, CHOrFIX, HEK293rFIX, and high-phospho/sulfo HEK293rFIX in FIX-knock-out mice. Plasma
concentrations of FIX after administration are shown as mean values ± standard deviations with n = 10 mice for each timepoint. Dose
adjustment was done by normalizing to start material concentrations.
Table 1 AUCs of pdFIX, CHOrFIX, HEK293rFIX, and high-phospho/sulfo HEK293rFIX in a FIX-knock-out mouse
pharmacokinetic study. Only relative AUC values are shown. Statistically significant different ratios to CHOrFIX (at the
5 % level) are marked with an asterisk*. The ratio of HEK293rFIX high phospho/sulfo to HEK293- total rFIX was also
statistically significantly different for both antigen and activity.
Relative value of AUC: antigen Relative value of AUC: clotting activity
pdFIX 1.5* 1.8*
CHOrFIX 11
HEK293rFIX high phospho/sulfo 0.7* 0.7*
HEK293rFIX 0.4* 0.4*
Böhm et al. BMC Proceedings 2011, 5(Suppl 8):P23
http://www.biomedcentral.com/1753-6561/5/S8/P23
Page 2 of 3from circulation. GalNAc were not found on N-glycans
on CHO-derived rFVII. Most oligosaccharides on
CHOrFVII were core fucosylated, biantennary structures
carrying two sialic acid residues. HEK293rFVII showed
major differences from all other rFVII forms, and, unex-
pectedly, from pdFVII. Most oligosaccharide structures
were not comparable to those published for pdFVII [3],
or found on rFVII from the other cell lines. A high con-
tent of fucosylation and terminal GalNAc, and a lower
degree of terminal sialic acids were measured, and tri-
or tetra-antennary structures were not found. Some oli-
gosaccharides were of a hybrid type with high-mannose
structures. These N-glycan structures do not favor the
use of HEK293 cells as a production platform for
human biotherapeutics, when protein recovery and half-
life in the circulation are of importance, and influenced
by N-glycosylation.
Pharmacokinetic differences between pdFIX and
CHO-derived rFIX were as expected from the literature;
HEK293rFIX materials (total rFIX and high phospho/
sulfo rFIX) were both inferior to CHO-derived rFIX in
t e r m so fa r e au n d e rt h ec u r v e( A U C )( T a b l e1 )a n din
vivo recovery. Similar terminal half-lives and mean resi-
dence times, but different in vivo recoveries between
rFIX and pdFIX preparations were confirmed by statisti-
cal analysis. High phospho/sulfo rFIX from HEK293 had
a larger AUC and in vivo recovery than total rFIX from
the same HEK293-derived clone and fermentation run,
indicating an influence of these modifications on phar-
macokinetics (Figure 1). Oligosaccharide mapping
showed high glycosylation heterogeneity for HEK293
and pdFIX, and more defined peak-groups representing
mono- to tetrasialylated glycans for CHO-derived mate-
rial. Sialic acid content of N-glycans was 25 % lower for
HEK293- than for CHOrFIX. Glycosylation and phos-
phorylation/sulfation degrees contributed to pharmaco-
kinetics of FIX preparations. If glycosylation was similar
in case of the two HEK293rFIX preparations, the effects
of phosphorylation and sulfation became evident.
In conclusion, these data showed that HEK293 cells
were not adequate for rFIX or rFVII production due to
improper N-glycosylation compared with the material
from other cell lines, or from human plasma. Conse-
quently, an advantage of this human cell line for the
production of “more-human-like” biotherapeutics could
not be observed.
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